Bullous Pemphigoid Associated with a new Combination Checkpoint Inhibitor Immunotherapy
Fontecilla, N.M..; Khanna, T.; Bayan, C.-A.Y..; Antonov, N.A..; Geskin, L.J..
Journal of Drugs in Dermatology Jdd 18(1): 103-104
2019
ISSN/ISBN: 1545-9616 PMID: 30681807 Document Number: 17698
Novel immunotherapies including antibodies to programmed death ligand 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have become common therapies for neoplasms including metastatic melanoma and non-small cell lung cancer (NSCLC). Dermatologic toxicity is the most common adverse event associated with these immunotherapies. We report a case of bullous pemphogoid (BP) in a patient receiving combination durvalumab and tremelimumab, two newer immunotherapy checkpoint inhibitors under investigation in phase III trials.
Document emailed within 1 workday
